Jazz Pharmaceuticals currently trades with a PE to growth ratio of 0.42, based on Nov 11, 2026 data. Dividing the 68.2 PE ratio by the 160.8% earnings growth rate produces this figure.
Historically, Jazz Pharmaceuticals has a PEG ratio averaging 0.92 across the last ten years. At 0.42, today's PEG ratio sits 54% less than its historical average. The ten years high came in the Sep 2017 quarter at 5.9, reflecting peak valuation relative to growth. The bottom was reached in the Jun 2024 quarter at 0.03, suggesting attractive value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | N/A | N/A | -164.5% |
| 2024 | 0.35 | 13.59 | 38.3% |
| 2023 | 0.07 | 18.78 | 283% |
| 2022 | N/A | N/A | 35.1% |
| 2021 | N/A | N/A | -229% |
| 2020 | N/A | 38.56 | -53.6% |
| 2019 | 0.68 | 16.19 | 23.8% |
| 2018 | N/A | 16.64 | -8.4% |
| 2017 | 0.69 | 16.56 | 23.9% |
| 2016 | 0.76 | 16.62 | 21.9% |
| 2015 | 0.06 | 26.13 | 449% |
| 2014 | N/A | 167.07 | -73.6% |
| 2013 | N/A | 34.11 | -27.1% |
| 2012 | 0.15 | 10.46 | 69.1% |
| 2011 | 0.05 | 12.83 | 234.4% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Sep 2026 | 0.4 | 63.6 | 160.8% |
| Jun 2026 | 0.05 | 15.79 | 330.2% |
| Mar 2026 | N/A | 402.23 | -94% |
| Dec 2025 | N/A | N/A | -164.5% |
| Sep 2025 | N/A | N/A | -180.4% |
| Jun 2025 | N/A | N/A | -205.6% |
| Mar 2025 | 0.33 | 15.94 | 48.9% |
| Dec 2024 | 0.35 | 13.59 | 38.3% |
| Sep 2024 | 0.03 | 14.95 | 520.8% |
| Jun 2024 | 0.03 | 17 | 536.1% |
| Mar 2024 | 0.07 | 23.02 | 308.4% |
| Dec 2023 | 0.07 | 18.78 | 283% |
| Sep 2023 | 0.19 | 107.87 | 561.5% |
| Jun 2023 | N/A | N/A | -77.8% |
| Mar 2023 | N/A | N/A | 66.4% |
JAZZ's PEG ratio today sits above the 3 and 5-year averages, but it is lower than the 10-year average.
Jazz Pharmaceuticals's PEG of 0.42 is higher than the industry average but lower than the Healthcare sector average. Looking at the Healthcare sector average of 0.62, Jazz Pharmaceuticals's PEG is 32% lower.
According to Nov 11, 2026 figures, JAZZ's PEG ratio stands at 0.42.
Across the past 3 years, JAZZ's PEG ratio has averaged at 0.17.
Across the past 5 years, JAZZ's PEG ratio has averaged at 0.17.
JAZZ's PEG ratio topped out at 5.9 during the Sep 2017 quarter - the highest in ten years.
Compared to the 10-year average, JAZZ's PEG ratio stands 54% lower.
At 0.42, JAZZ's PEG ratio suggests the stock may be undervalued given its growth rate.
To calculate the PEG ratio, take the company's PE ratio and divide by its earnings per share growth (YoY TTM). As of Nov 11, 2026, Jazz Pharmaceuticals has a PE ratio of 68.2. Earnings grew at 160.8% over the TTM period ending Sep 2026. Applying the formula, this gives a PEG ratio of 0.42. PEG RATIO(0.42) = PE RATIO(68.2) / EPS GROWTH(160.8%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.